| 生物活性 |
Acetyl zingerone is a Zingerone (MS-X11849) analog that downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes, inhibits the activities of MMP-1, MMP-3, and MMP-12 as well as NLRP3 inflammasome activation, pyroptosis, ferroptosis, cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation, while upregulating the expression of collagen, proteoglycans, extracellular matrix glycoproteins, the Notch pathway, and GPX4, activating Nrf2 and HO-1, inducing extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy, promoting chondrocyte survival, alleviating osteoarthritis progression in mice, and serving as a potential agent for research on skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer. |
体外研究 (In Vitro) |
Acetyl zingerone 可改变重组人表皮中的基因表达,上调核心基质组、Notch 及 ERK1/ERK2 通路基因,同时下调炎症相关、TGF-β 信号通路及 AP-1/NF-κB 相关基因。 Acetyl zingerone (10-200 µg/mL; 6 day) 可呈剂量依赖性地提高培养的人皮肤成纤维细胞中单位细胞密度下的细胞外基质蛋白丰度。 Acetyl zingerone (10 µL/cm2; 每日 1 次,连续 4 天) 可使体外人面部皮肤活检样本的真皮胶原蛋白含量增加 2 倍。 Acetyl zingerone (从将 0.1 g AZ 溶解于 1 mL DMSO 制备的储备液开始进行 1:1 系列稀释;10 min (MMP-1, MMP-3); 15 min (MMP-12)) 可在无细胞实验中抑制 MMP-1、MMP-3 和 MMP-12 的活性,其中对 MMP-12 的抑制效力最强 (IC50 = 0.255 mg),其次是 MMP-3 (IC50 = 0.505 mg) 和 MMP-1 (IC50 = 1.065 mg)。 Acetyl zingerone 可逆转重组人表皮中与成纤维细胞衰老、角质形成细胞分化及 IL-17A 刺激相关的基因表达模式。 Acetyl zingerone (25-200 μM; 2-48 h) 对 ATDC5 软骨细胞有保护作用,可使其免受 LPS (MS-X54539)+ ATP (MS-D18391) 诱导的细胞毒性损伤并恢复增殖能力。 Acetyl zingerone (100 μM; 24 h) 可通过减轻细胞膜损伤、抑制 NLRP3 炎症小体活化及下游焦亡相关蛋白的表达,抑制 LPS + ATP 诱导的 ATDC5 软骨细胞焦亡。 Acetyl zingerone (100 μM; 24 h) 可通过降低 ROS/mtROS 生成、恢复线粒体膜电位与结构完整性,减轻 LPS + ATP 诱导的 ATDC5 软骨细胞线粒体损伤。 Acetyl zingerone (100 μM; 24 h pretreatment, 24 h LPS + ATP induction) 可激活经 LPS + ATP 处理的 ATDC5 软骨细胞中由 PINK1/Parkin 介导的线粒体自噬。 Acetyl zingerone (25-100 μM; 24-48 h) 提升经 IL-1β 处理的原代大鼠软骨细胞的存活率,恢复细胞的增殖能力。 Acetyl zingerone (25-100 μM; 24 h) 可通过上调聚集蛋白聚糖与 COL2A1、下调基质降解酶及炎性因子,维持经 IL-1β 处理的原代大鼠软骨细胞与小鼠 ATDC5 成软骨细胞的 ECM 稳态。 Acetyl zingerone (25-100 μM; 24 h) 可通过上调 Notch1 和 SOCS3、降低活化型 caspase-3 水平,抑制 IL-1β 诱导的经 IL-1β 处理的原代大鼠软骨细胞及小鼠 ATDC5 软骨发生细胞凋亡。 Acetyl zingerone (25-100 μM; 24 h) 可减少 IL-1β 诱导的原代大鼠软骨细胞内 ROS 的累积。 Acetyl zingerone (100 μM; 24 h) 可通过提升 GSH 水平、降低 MDA 水平、稳定线粒体结构以及上调 GPX4,激活 Nrf2/HO-1 通路,抑制 IL-1β 诱导的原代大鼠软骨细胞和小鼠 ATDC5 软骨生成细胞铁死亡。 Acetyl zingerone (25 µg/mL; 1-6 h post-UVA irradiation) 可显著降低 C57BL/6 小鼠黑素细胞在 UVA 照射后最初 2 小时内的暗态环丁烷嘧啶二聚体 (dark-CPD) 形成,照射后 1 小时时抑制率约达 82%,且不会损伤 DNA 修复功能或细胞活力。 Acetyl zingerone (25-50 µg/mL; 20 min pre-incubation prior to 25 min UVA irradiation) 可呈剂量依赖性地降低 UVA 诱导的人正常新生儿表皮角质形成细胞内 ROS 生成,降幅分别为 35% 和 46%。
ELISA Assay
| Cell Line: |
Cultured human dermal fibroblasts |
| Concentration: |
0, 10, 25, 50, 100, 200 µg/mL |
| Incubation Time: |
6 day |
| Result: |
Increased protein abundance per unit cell density (P < 0.05) in a dose-dependent manner for type I, IV, and VI collagens; fibromodulin; transforming growth factor-β; fibronectin; TIMP-1; and vimentin. Showed greater abundance with higher AZ concentrations, with significant differences from control observed at specific doses (e.g., type I collagen at 100 µg/mL, type IV collagen at 50 and 100 µg/mL). |
Cell Viability Assay
| Cell Line: |
ATDC5 chondrocytes |
| Concentration: |
25, 50, 100, 200 μM |
| Incubation Time: |
24 h, 48 h (co-treatment with LPS + ATP); 24 h (treatment with LPS + ATP), 2 h (EdU (MS-P82191) incubation) |
| Result: |
Shows no cytotoxicity at concentrations below 100 μM. Significantly reduces cell viability at 200 μM after 24 h and 48 h. Mitigates LPS + ATP-induced cytotoxicity, with 100 μM producing the most pronounced improvement in cell viability. Reverses LPS + ATP-induced inhibition of chondrocyte proliferation, with 100 μM being the most effective concentration. |
Cell Autophagy Assay
| Cell Line: |
ATDC5 chondrocytes |
| Concentration: |
100 μM |
| Incubation Time: |
24 h pretreatment, followed by 24 h LPS + ATP induction |
| Result: |
Significantly increases the expression of PINK1, Parkin, and LC3-II, and decreases p62 expression in LPS + ATP-treated chondrocytes. Enhances PINK1 and Parkin expression, which is suppressed by chloroquine (CQ) via immunofluorescence. Increases co-localization of Parkin and LC3B with mitochondria, enhances autolysosome formation, and promotes mitophagic clearance of damaged mitochondria; these effects are attenuated by CQ. Reduces LPS + ATP-induced ROS and mtROS production, an effect reversed by CQ. |
Apoptosis Analysis
| Cell Line: |
primary rat chondrocytes, mouse ATDC5 chondrogenic cells |
| Concentration: |
25, 50 and 100 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced IL-1β-induced apoptosis (lower early + late apoptotic cell proportion), increased cell number, upregulated Notch1 and SOCS3 expression, and decreased the cleaved caspase-3/caspase-3 ratio compared with the IL-1β-treated group. Flow cytometry confirmed the anti-apoptotic effect at 100 μM, while crystal violet staining and western blot showed dose-dependent effects at 25, 50, and 100 μM. Produced similar results in mouse ATDC5 cells. |
Western Blot Analysis
| Cell Line: |
primary rat chondrocytes |
| Concentration: |
100 μM |
| Incubation Time: |
24 h |
| Result: |
Upregulated Nrf2, HO-1, and GPX4 expression compared with the IL-1β-treated group. Had its protective effect on GPX4 expression abolished by Nrf2 or HO-1 inhibitors, which exacerbated IL-1β-induced GPX4 suppression. |
ELISA Assay
| Cell Line: |
C57BL/6 mouse melanocytes |
| Concentration: |
25 µg/mL |
| Incubation Time: |
1, 2, 4, 6 h post-UVA irradiation |
| Result: |
Significantly reduced dark-CPD formation within the first 2 h post-irradiation, with an ~82% reduction observed after 1 h compared to controls. Matched control CPD levels by 6 h post-irradiation, indicating no interference with DNA repair. Left cell viability unaffected. |
|
体内研究 (In Vivo) |
Acetyl zingerone (1 mg/kg;关节腔内注射;每周 2 次;持续 8 周) 可通过促进 PINK1/Parkin 介导的线粒体自噬、抑制软骨细胞焦亡、减轻软骨损伤及恢复软骨下骨重塑,缓解内侧半月板失稳模型 (DMM) 诱导小鼠的骨关节炎进展。
| Animal Model: |
C57BL/6 J (male, 8-week-old, DMM surgery-induced osteoarthritis) |
| Dosage: |
1 mg/kg |
| Administration: |
intra-articular injection; twice a week; 8 weeks |
| Result: |
Significantly reduced calcified menisci and bone remnants compared to the DMM-only group. Normalized subchondral bone microarchitecture parameters, increasing bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) relative to the DMM-only group. Reduced cartilage loss and proteoglycan depletion, lowering Osteoarthritis Research Society International (OARSI) scores compared to the DMM-only group. Decreased immunohistochemical staining of pyroptosis-related protein NLRP3 and matrix-degrading protein MMP13 in cartilage tissues relative to the DMM-only group. Increased immunohistochemical staining of mitophagy-related proteins Parkin and LC3B, as well as matrix-synthesizing protein Collagen II, in cartilage tissues relative to the DMM-only group. |
|